Thrombolytic Therapy

Abstract

IN the continuing search for new and improved methods of treating thromboembolic diseases, the concept of an agent to dissolve clots has always been attractive. After the efficacy of heparin in venous thromboembolism was established by Barritt and Jordan,¹ many physicians regarded its use as definitive, but in reality its action was only preventive. What was needed was an agent that would act on the morbid event directly — i.e., that would dissolve thromboemboli in pulmonary embolism. By restoring pulmonary vascular space, relieving pulmonary hypertension, and recompensating right ventricular function, such therapy could minimize morbidity and perhaps decrease mortality, particularly . . .